Insider Selling: Phreesia, Inc. (NYSE:PHR) Director Sells 20,565 Shares of Stock

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 20,565 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $25.04, for a total value of $514,947.60. Following the completion of the transaction, the director now owns 242,827 shares of the company’s stock, valued at $6,080,388.08. This trade represents a 7.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Weintraub also recently made the following trade(s):

• On Monday, December 16th, Michael Weintraub sold 861 shares of Phreesia stock. The shares were sold at an average price of $25.26, for a total value of $21,748.86.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The stock was sold at an average price of $21.01, for a total value of $318,343.52.

Phreesia Stock Performance

NYSE PHR opened at $23.84 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The stock has a 50-day moving average of $20.73 and a 200 day moving average of $21.91. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -16.22 and a beta of 0.98.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same quarter last year, the business earned ($0.58) earnings per share. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. Sell-side analysts anticipate that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Champlain Investment Partners LLC boosted its position in Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after acquiring an additional 97,847 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after purchasing an additional 42,973 shares during the last quarter. State Street Corp grew its position in shares of Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after purchasing an additional 55,934 shares in the last quarter. Finally, TimesSquare Capital Management LLC increased its holdings in shares of Phreesia by 2.3% in the third quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company’s stock valued at $19,791,000 after purchasing an additional 19,395 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, September 9th. DA Davidson reissued a “buy” rating and set a $32.00 target price on shares of Phreesia in a report on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price target on shares of Phreesia in a report on Friday, September 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Finally, Robert W. Baird decreased their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Phreesia currently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.